Technical Analysis for ALNA - Allena Pharmaceuticals, Inc.

Grade Last Price % Change Price Change
grade F 9.73 -3.18% -0.32
ALNA closed down 3.18 percent on Wednesday, January 17, 2018, on 27 percent of normal volume. Note that the stock is in oversold territory based on its Slow Stochastic indicator (14, 3, 3) -- sideways movement or a bounce should not be unexpected.
0 Watchers
Track This Stock
Watchlist Portfolio

Trend Table & Recent Alerts
ADX Long-Term Intermediate-Term Short-Term
Weak or Absent N/A Down Down
See historical ALNA trend table...

Date Alert Name Type % Chg
Jan 17 New 52 Week Closing Low Bearish 0.00%
Jan 17 Stochastic Reached Oversold Weakness 0.00%
Jan 17 Wide Bands Range Expansion 0.00%
Jan 17 Lower Bollinger Band Touch Weakness 0.00%
Jan 17 Oversold Stochastic Weakness 0.00%
Jan 16 Multiple of Ten Bullish Other -3.18%
Jan 16 Outside Day Range Expansion -3.18%
Jan 16 Wide Bands Range Expansion -3.18%
Jan 16 Oversold Stochastic Weakness -3.18%
Jan 12 Narrow Range Bar Range Contraction -4.98%

Older signals for ALNA ...

Get a Trading Assistant

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.
Configure default chart indicators
Basic chart:

Profile
Allena Pharmaceuticals, Inc. is a United States-based specialty biopharmaceutical company. The Company is focused on developing and commercializing non-systemic oral protein therapeutics to treat metabolic and orphan diseases, with a particular focus on nephrologic and urologic conditions. Its lead product candidate, ALLN-177, is in an ongoing Phase II clinical trial and is being developed for the chronic management of hyperoxaluria and kidney stones. ALLN-177 is an orally administered, recombinant oxalate-degrading enzyme. ALLN-177 targets oxalate in the gastrointestinal (GI) tract to reduce the burden of both dietary and endogenously produced oxalate. ALLN-177 has the potential to decrease the oxalate available systemically for deposition as calcium oxalate crystals or stones in the kidneys, as well as to reduce the incidence of calcium oxalate related complications. Its technological approach enables the design and development of oral protein therapies that remain in the GI tract.
Is ALNA a Buy, Sell or Hold?
Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength
Summary: Counts: 0 bullish, 2 bearish and 3 neutral indicators. You may wish to incorporate that into your trading strategies.
Indicators
Indicator Value
52 Week High 15.4
52 Week Low 8.66
Average Volume 89,971
200-Day Moving Average 0.0
50-Day Moving Average 11.9272
20-Day Moving Average 10.366
10-Day Moving Average 10.248
Average True Range 0.7126
ADX 24.15
+DI 16.92
-DI 26.23
Chandelier Exit (Long, 3 ATRs ) 11.5822
Chandelier Exit (Short, 3 ATRs ) 11.6578
Upper Bollinger Band 11.0296
Lower Bollinger Band 9.7024
Percent B (%b) 0.02
BandWidth 12.803396
MACD Line -0.5484
MACD Signal Line -0.5242
MACD Histogram -0.0242
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 10.30
Resistance 3 (R3) 10.33 10.16 10.21
Resistance 2 (R2) 10.16 10.02 10.15 10.17
Resistance 1 (R1) 9.95 9.93 9.87 9.92 10.14
Pivot Point 9.78 9.78 9.74 9.77 9.78
Support 1 (S1) 9.57 9.64 9.49 9.54 9.32
Support 2 (S2) 9.40 9.55 9.39 9.29
Support 3 (S3) 9.19 9.40 9.26
Support 4 (S4) 9.16